US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CG Oncology Inc.

25.55

-0.7300-2.78%

Post-market: 25.550.0020+0.01%17:01 EDT

Volume:987.48K

Turnover:25.34M

Market Cap:1.95B

PE:-16.89

High:26.46

Open:26.45

Low:25.43

Close:26.28

Loading ...

Overview Company News Filings

CG Oncology Is Maintained at Overweight by Morgan Stanley

Analysts Offer Insights on NA Companies: Copa Holdings (CPA) and CG Oncology, Inc. (CGON)

CG Oncology Holds 2025 Annual Stockholders Meeting

CG Oncology Inc. Conducted Annual Stockholders Meeting

Promising Market Position and Investment Opportunity: CG Oncology’s Creto in NMIBC Treatment

Leonard E. Post, Director, Reports Disposal of Common Shares in CG Oncology Inc

CG Oncology Is Maintained at Overweight by Morgan Stanley

Promising Outlook for CG Oncology: Strong Financial Health and Positive Trial Results for Cretostimogene

Promising Prospects for CG Oncology’s Cretostimogene in NMIBC Treatment: Superior Efficacy and Strategic Expansion

CG Oncology Q1 Loss Widens, Revenue Falls

MT Newswires Live

CG Oncology Reports Q1 2025 Net Loss of $34.5 Million, EPS at ($0.45), Compared to $16.9 Million Loss in Q1 2024

Earnings Flash (CGON) CG Oncology Posts Q1 License and Collaboration Revenue $52,000, vs. FactSet Est of $200,000

MT Newswires Live

Earnings Flash (CGON) CG Oncology Posts Q1 Net Loss $0.45 a Share, vs. FactSet Est of $0.40 Loss

MT Newswires Live

CG Oncology Q1 EPS $(0.45) Misses $(0.41) Estimate, Sales $52.00K Miss $212.75K Estimate

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

THOMSON REUTERS

CG Oncology Inc: Qtrly Loss per Share $0.45

THOMSON REUTERS

Press Release: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

CG Oncology Initiated at Overweight by JP Morgan

JPMorgan Initiates Coverage on CG Oncology With Overweight Rating, $41 Price Target

MT Newswires Live

CG Oncology initiated with an Overweight at JPMorgan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CGON/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CGON","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CGON\",,,,,undefined,":{"symbol":"CGON","market":"US","secType":"STK","nameCN":"CG Oncology Inc.","latestPrice":25.55,"timestamp":1750449600000,"preClose":26.28,"halted":0,"volume":987475,"hourTrading":{"tag":"盘后","latestPrice":25.55,"preClose":25.548,"latestTime":"17:01 EDT","volume":213998,"amount":5467648.2072,"timestamp":1750453260446},"delay":0,"floatShares":61126461,"shares":76225308,"eps":-1.512766,"marketStatus":"Market Closed","change":-0.73,"latestTime":"06-20 16:00:00 EDT","open":26.45,"high":26.46,"low":25.43,"amount":25344395.1035,"amplitude":0.039193,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.512766,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750665600000},"marketStatusCode":7,"adr":0,"listingDate":1706158800000,"exchange":"NASDAQ","adjPreClose":26.28,"preHourTrading":{"tag":"盘前","latestPrice":26.3,"preClose":26.28,"latestTime":"09:27 EDT","volume":880,"amount":23167.70104,"timestamp":1750426060083},"postHourTrading":{"tag":"盘后","latestPrice":25.55,"preClose":25.548,"latestTime":"17:01 EDT","volume":213998,"amount":5467648.2072,"timestamp":1750453260446},"volumeRatio":1.12153057934611,"optionData":{"bulkOrders":[{"symbol":"CGON","call":true,"expireDate":1750392000000,"strike":"25.0","timestamp":1750437161888,"price":1.01,"volume":3000,"amount":303000,"type":"-"},{"symbol":"CGON","call":true,"expireDate":1752811200000,"strike":"25.0","timestamp":1750437161888,"price":2.06,"volume":3000,"amount":618000,"type":"-"}]},"impliedVol":0.6456,"impliedVolPercentile":0.424},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CGON\",,,,,undefined,":{"symbol":"CGON","floatShares":61126461,"roa":"-12.85%","roe":"-16.57%","lyrEps":-1.408697,"volumeRatio":1.12153057934611,"shares":76225308,"dividePrice":0,"high":26.46,"amplitude":0.039193,"preClose":26.28,"low":25.43,"week52Low":14.8,"pbRate":"2.76","psRate":"2941.93","week52High":40.47,"institutionHeld":0,"latestPrice":25.55,"eps":-1.512766,"divideRate":0,"volume":987475,"delay":0,"ttmEps":-1.512766,"open":26.45,"prevYearClose":28.68,"prevWeekClose":25.86,"prevMonthClose":25.62,"prevQuarterClose":24.49,"fiveDayClose":26.5,"twentyDayClose":26.22,"sixtyDayClose":27.54},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CGON\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2544996193","title":"CG Oncology Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2544996193","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544996193?lang=en_us&edition=fundamental","pubTime":"2025-06-17 23:13","pubTimestamp":1750173180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGON/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 17, 2025 11:13 ET (15:13 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CG","CGON"],"gpt_icon":0},{"id":"2544966087","title":"Analysts Offer Insights on NA Companies: Copa Holdings (CPA) and CG Oncology, Inc. (CGON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2544966087","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544966087?lang=en_us&edition=fundamental","pubTime":"2025-06-17 18:40","pubTimestamp":1750156838,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Copa Holdings (CPA – Research Report) and CG Oncology, Inc. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-copa-holdings-cpa-and-cg-oncology-inc-cgon-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-copa-holdings-cpa-and-cg-oncology-inc-cgon-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4008","BK4135","CGON","BK4141","CG","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4139","CPA","NA","BK4500"],"gpt_icon":0},{"id":"2541589512","title":"CG Oncology Holds 2025 Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2541589512","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541589512?lang=en_us&edition=fundamental","pubTime":"2025-06-07 05:06","pubTimestamp":1749244009,"startTime":"0","endTime":"0","summary":"CG Oncology, Inc. ( ($CGON) ) just unveiled an update. On June 5, 2025, CG Oncology, Inc. held its 2025 Annual Meeting of Stockholders where key de...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cg-oncology-holds-2025-annual-stockholders-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cg-oncology-holds-2025-annual-stockholders-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B64PRP62.GBP","CGON","CG","IE00BGHQF748.EUR","BK4139","IE00B3QW5Z07.USD","BK4135"],"gpt_icon":0},{"id":"2541898292","title":"CG Oncology Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2541898292","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541898292?lang=en_us&edition=fundamental","pubTime":"2025-06-07 04:16","pubTimestamp":1749240978,"startTime":"0","endTime":"0","summary":"CG Oncology Inc. held its 2025 Annual Meeting of Stockholders on June 5, 2025. Stockholders voted on the election of three Class I directors: Arthur Kuan, James J. Mulé, and Leonard Post. All three were elected. Additionally, stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 06, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL12ht1f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","BK4139"],"gpt_icon":0},{"id":"2540416764","title":"Promising Market Position and Investment Opportunity: CG Oncology’s Creto in NMIBC Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2540416764","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540416764?lang=en_us&edition=fundamental","pubTime":"2025-06-02 18:15","pubTimestamp":1748859352,"startTime":"0","endTime":"0","summary":"Brian Cheng, an analyst from J.P. Morgan, maintained the Buy rating on CG Oncology, Inc. (CGON – Research Report). The associated price target rema...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-market-position-and-investment-opportunity-cg-oncologys-creto-in-nmibc-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-market-position-and-investment-opportunity-cg-oncologys-creto-in-nmibc-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0234570918.USD","LU1074936037.SGD","LU0098860793.USD","CGON","LU2271345857.HKD","LU1668664300.SGD","LU2089283258.USD","LU2133065610.SGD","LU0314104364.USD","IE00B64PRP62.GBP","LU0106831901.USD","LU1720051017.SGD","LU2089284900.SGD","LU1732799900.SGD","LU1989772923.USD","IE00B3QW5Z07.USD","LU2347655156.SGD","CG","LU0267386448.USD","LU1162221912.USD","LU2023251221.USD","BK4135","IE00BKVL7J92.USD","LU0158827948.USD","LU2357305700.SGD","BK4585","LU0912757837.SGD","LU1548497426.USD","LU2111349929.HKD","LU1732800096.USD","BK4534","LU0106261372.USD","IE00BGHQF748.EUR","BK4127","LU1363072403.SGD","LU2028103732.USD","BK4504","BK4139","LU0971096721.USD","LU1989772840.SGD","LU0320765646.SGD","LU0158827781.USD","LU0795875086.SGD","BK4516","BK4581","LU0006306889.USD","IE00BZ1G4Q59.USD","BK4588","LU0225283273.USD","LU0795875169.SGD"],"gpt_icon":0},{"id":"2537922590","title":"Leonard E. Post, Director, Reports Disposal of Common Shares in CG Oncology Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2537922590","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537922590?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:15","pubTimestamp":1747944951,"startTime":"0","endTime":"0","summary":"Leonard E. Post, a Director at CG Oncology Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL4xwLRg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","BK4139"],"gpt_icon":0},{"id":"2536633817","title":"CG Oncology Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2536633817","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536633817?lang=en_us&edition=fundamental","pubTime":"2025-05-19 22:43","pubTimestamp":1747665780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGON/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 19, 2025 10:43 ET (14:43 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","CG"],"gpt_icon":0},{"id":"2535081694","title":"Promising Outlook for CG Oncology: Strong Financial Health and Positive Trial Results for Cretostimogene","url":"https://stock-news.laohu8.com/highlight/detail?id=2535081694","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535081694?lang=en_us&edition=fundamental","pubTime":"2025-05-14 03:05","pubTimestamp":1747163110,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on CGON stock, giving a Buy rating today. Sam Slutsky has given his Buy rat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-outlook-for-cg-oncology-strong-financial-health-and-positive-trial-results-for-cretostimogene?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-outlook-for-cg-oncology-strong-financial-health-and-positive-trial-results-for-cretostimogene?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B64PRP62.GBP","CGON","CG","IE00BGHQF748.EUR","BK4135","IE00B3QW5Z07.USD","BK4139"],"gpt_icon":0},{"id":"2535649703","title":"Promising Prospects for CG Oncology’s Cretostimogene in NMIBC Treatment: Superior Efficacy and Strategic Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2535649703","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535649703?lang=en_us&edition=fundamental","pubTime":"2025-05-13 22:45","pubTimestamp":1747147510,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) today and set a price target of $...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-prospects-for-cg-oncologys-cretostimogene-in-nmibc-treatment-superior-efficacy-and-strategic-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-prospects-for-cg-oncologys-cretostimogene-in-nmibc-treatment-superior-efficacy-and-strategic-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGON","BK4139","IE00BGHQF748.EUR","BK4135","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","CG"],"gpt_icon":0},{"id":"2535778943","title":"CG Oncology Q1 Loss Widens, Revenue Falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2535778943","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535778943?lang=en_us&edition=fundamental","pubTime":"2025-05-13 20:32","pubTimestamp":1747139545,"startTime":"0","endTime":"0","summary":"CG Oncology  reported a Q1 net loss Tuesday of $0.45 per share, widening from a loss of $0.36 a year earlier.Analysts surveyed by FactSet expected a loss of $0.40 per share.License and collaboration revenue for the quarter ended March 31 was $52,000, down from $529,000 a year earlier.Analysts surveyed by FactSet expected $200,000.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CG","CGON"],"gpt_icon":0},{"id":"2535720652","title":"CG Oncology Reports Q1 2025 Net Loss of $34.5 Million, EPS at ($0.45), Compared to $16.9 Million Loss in Q1 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2535720652","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535720652?lang=en_us&edition=fundamental","pubTime":"2025-05-13 20:15","pubTimestamp":1747138551,"startTime":"0","endTime":"0","summary":"CG Oncology, Inc. , a late-stage clinical biopharmaceutical company, announced its financial results for the first quarter ended March 31, 2025. The company reported a net loss of $34.5 million for the quarter, compared to a net loss of $16.9 million for the same period in 2024. The increase in net loss was primarily due to higher personnel-related expenses, including compensation costs from increased headcount, as well as elevated professional and consultant fees and marketing-related costs. The company's cash position, including cash equivalents and marketable securities, was $688.4 million as of March 31, 2025, down from $742.0 million as of December 31, 2024. CG Oncology continues to focus on developing and commercializing therapies for bladder cancer, with significant progress in its clinical programs. Key business updates include the presentation of updated BOND-003 clinical results at the American Urological Association  meeting, showing promising durability and tolerability dat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL2Fm8r3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON"],"gpt_icon":0},{"id":"2535205197","title":"Earnings Flash (CGON) CG Oncology Posts Q1 License and Collaboration Revenue $52,000, vs. FactSet Est of $200,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2535205197","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535205197?lang=en_us&edition=fundamental","pubTime":"2025-05-13 20:13","pubTimestamp":1747138382,"startTime":"0","endTime":"0","summary":"Earnings Flash (CGON) CG Oncology Posts Q1 License and Collaboration Revenue $52,000, vs. FactSet Est of $200,000","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CG","CGON"],"gpt_icon":0},{"id":"2535727034","title":"Earnings Flash (CGON) CG Oncology Posts Q1 Net Loss $0.45 a Share, vs. FactSet Est of $0.40 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2535727034","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535727034?lang=en_us&edition=fundamental","pubTime":"2025-05-13 20:09","pubTimestamp":1747138175,"startTime":"0","endTime":"0","summary":"Earnings Flash (CGON) CG Oncology Posts Q1 Net Loss $0.45 a Share, vs. FactSet Est of $0.40 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CGON","CG"],"gpt_icon":0},{"id":"2535172726","title":"CG Oncology Q1 EPS $(0.45) Misses $(0.41) Estimate, Sales $52.00K Miss $212.75K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535172726","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535172726?lang=en_us&edition=fundamental","pubTime":"2025-05-13 20:06","pubTimestamp":1747137981,"startTime":"0","endTime":"0","summary":"CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.41) by 9.76 percent. This is a 25 percent decrease over losses of $(0.36) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45373026/cg-oncology-q1-eps-0-45-misses-0-41-estimate-sales-52-00k-miss-212-75k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","CG"],"gpt_icon":0},{"id":"2535727384","title":"CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2535727384","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535727384?lang=en_us&edition=fundamental","pubTime":"2025-05-13 20:00","pubTimestamp":1747137606,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA4DHQCH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGON","BK4139"],"gpt_icon":0},{"id":"2535720644","title":"CG Oncology Inc: Qtrly Loss per Share $0.45","url":"https://stock-news.laohu8.com/highlight/detail?id=2535720644","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535720644?lang=en_us&edition=fundamental","pubTime":"2025-05-13 20:00","pubTimestamp":1747137606,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA4DHQCH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGON","BK4139"],"gpt_icon":0},{"id":"2535279547","title":"Press Release: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2535279547","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535279547?lang=en_us&edition=fundamental","pubTime":"2025-05-13 20:00","pubTimestamp":1747137600,"startTime":"0","endTime":"0","summary":"- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -. - Promising early signal in Cohort P with 90.5% high-grade recurrence free survival at 3 and 9 months by K-M -. - Initiated CORE-008 Cohort CX evaluating the combination of cretostimogene and gemcitabine in patients with high-risk  BCG-exposed NMIBC -. \"In 2025, we made further progress advancing cretostimogene monotherapy as a bladder-sparing backbone therapy for patients with NMIBC,\" said Arthur Kuan, Chairman & Chief Executive Officer at CG Oncology. \"With best-in-disease durability and tolerability data from the BOND-003 Cohort C registrational trial recently presented at AUA, we are well positioned to initiate our BLA submission in the second half of the year for the treatment of patients with HR NMIBC unresponsive to BCG. Our clinical programs have been carefully designed to address different stages of b","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","US30Y.BOND","US6M.BOND","US12M.BOND","IE00BGHQF748.EUR","CR","US2Y.BOND","US10Y.BOND","IE00B64PRP62.GBP","BK4135","US5Y.BOND","BK4161","US3Y.BOND","BK4225","BK4203","CGON","CG","HR","US7Y.BOND","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2532184886","title":"CG Oncology Initiated at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2532184886","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532184886?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:56","pubTimestamp":1746186960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGON/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 02, 2025 07:56 ET (11:56 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","CG"],"gpt_icon":0},{"id":"2532526817","title":"JPMorgan Initiates Coverage on CG Oncology With Overweight Rating, $41 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2532526817","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532526817?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:22","pubTimestamp":1746184976,"startTime":"0","endTime":"0","summary":"CG Oncology (CGON) has an average rating of Buy and mean price target of $60.22, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CG","JPM","CGON"],"gpt_icon":0},{"id":"2532813356","title":"CG Oncology initiated with an Overweight at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2532813356","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532813356?lang=en_us&edition=fundamental","pubTime":"2025-05-02 17:10","pubTimestamp":1746177038,"startTime":"0","endTime":"0","summary":"JPMorgan initiated coverage of CG Oncology (CGON) with an Overweight rating and $41 price target The company is developing the first oncolytic vira...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cg-oncology-initiated-with-an-overweight-at-jpmorgan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cg-oncology-initiated-with-an-overweight-at-jpmorgan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGON","CG"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":94,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CGON\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-13","symbol":"CGON","fiscalQuarterEnding":"2025/03","expectedEps":-0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"pre","actualEps":-0.45},{"market":"US","date":"2025-03-28","symbol":"CGON","fiscalQuarterEnding":"2024/12","expectedEps":-0.41,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743134400000,"reportTimeType":"pre","actualEps":-0.48},{"market":"US","date":"2024-11-12","symbol":"CGON","fiscalQuarterEnding":"2024/09","expectedEps":-0.42,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CGON\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CGON\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1,"buy":0.8,"hold":0.1,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":10,"updateTime":1746244800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CGON\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CGON","date":"2025-06-20","current":-18.977435,"percent":0.903614,"low":-77.942097,"twenty":-49.032283,"median":-37.168124,"eighty":-26.449487,"high":-13.496527,"avg":-38.172694,"sd":14.718632,"marketCap":2003201094},"quantilePoints":[{"date":"2024-01-26","current":-62.124194,"twenty":-62.124194,"median":-62.124194,"eighty":-62.124194,"marketCap":2539823423},{"date":"2024-02-02","current":-61.712969,"twenty":-61.712969,"median":-60.379514,"eighty":-59.355029,"marketCap":2523011292},{"date":"2024-02-09","current":-63.452965,"twenty":-62.124194,"median":-60.590915,"eighty":-59.355029,"marketCap":2594147579},{"date":"2024-02-16","current":-77.177799,"twenty":-70.608092,"median":-61.918582,"eighty":-60.168112,"marketCap":3155259972},{"date":"2024-02-23","current":-75.080046,"twenty":-72.448911,"median":-64.672589,"eighty":-60.20714,"marketCap":3069497532},{"date":"2024-03-01","current":-72.705845,"twenty":-73.870179,"median":-70.608092,"eighty":-60.516111,"marketCap":2972433066},{"date":"2024-03-08","current":-64.818944,"twenty":-72.891228,"median":-69.827533,"eighty":-60.799064,"marketCap":2649992888},{"date":"2024-03-15","current":-60.493345,"twenty":-72.302556,"median":-67.469593,"eighty":-60.20714,"marketCap":2473149409},{"date":"2024-03-22","current":-66.867912,"twenty":-72.162706,"median":-65.355579,"eighty":-60.438055,"marketCap":2733760852},{"date":"2024-03-28","current":-56.207672,"twenty":-71.967566,"median":-64.762028,"eighty":-59.842879,"marketCap":2732086332},{"date":"2024-04-05","current":-51.752186,"twenty":-71.648838,"median":-63.50175,"eighty":-58.14191,"marketCap":2515518513},{"date":"2024-04-12","current":-54.631116,"twenty":-71.284577,"median":-62.382039,"eighty":-56.136384,"marketCap":2655454642},{"date":"2024-04-19","current":-48.420853,"twenty":-71.001624,"median":-61.712969,"eighty":-54.576279,"marketCap":2353592420},{"date":"2024-04-26","current":-49.627262,"twenty":-70.73168,"median":-60.54213,"eighty":-53.208102,"marketCap":2412232322},{"date":"2024-05-03","current":-54.151294,"twenty":-70.286112,"median":-60.183337,"eighty":-53.600185,"marketCap":2632131954},{"date":"2024-05-10","current":-35.176138,"twenty":-69.778748,"median":-59.371617,"eighty":-52.278619,"marketCap":2000537303},{"date":"2024-05-17","current":-36.289307,"twenty":-68.393255,"median":-58.232975,"eighty":-49.860318,"marketCap":2063845445},{"date":"2024-05-24","current":-35.140985,"twenty":-67.52163,"median":-57.330453,"eighty":-49.032283,"marketCap":1998538098},{"date":"2024-05-31","current":-40.179539,"twenty":-67.228921,"median":-56.207672,"eighty":-47.173317,"marketCap":2285090743},{"date":"2024-06-07","current":-40.894311,"twenty":-66.477632,"median":-55.878652,"eighty":-42.192617,"marketCap":2325741235},{"date":"2024-06-14","current":-40.788853,"twenty":-65.885708,"median":-55.522213,"eighty":-41.278647,"marketCap":2319743621},{"date":"2024-06-21","current":-37.625109,"twenty":-65.85969,"median":-54.631116,"eighty":-40.788853,"marketCap":2139815216},{"date":"2024-06-28","current":-35.445642,"twenty":-65.443392,"median":-54.494024,"eighty":-40.683395,"marketCap":2015864537},{"date":"2024-07-05","current":-36.125261,"twenty":-64.796178,"median":-54.151294,"eighty":-39.560851,"marketCap":2054515824},{"date":"2024-07-12","current":-40.378738,"twenty":-64.675841,"median":-53.136814,"eighty":-38.206301,"marketCap":2296419569},{"date":"2024-07-15","current":-41.491907,"twenty":-64.64657,"median":-52.780375,"eighty":-38.236766,"marketCap":2359727711},{"date":"2024-08-02","current":-39.652248,"twenty":-64.6173,"median":-52.752957,"eighty":-38.267232,"marketCap":2255102676},{"date":"2024-08-09","current":-38.949194,"twenty":-63.924553,"median":-51.752186,"eighty":-38.000071,"marketCap":2215118586},{"date":"2024-08-16","current":-40.572681,"twenty":-63.472479,"median":-49.956283,"eighty":-38.105529,"marketCap":2307449488},{"date":"2024-08-23","current":-42.377221,"twenty":-62.965116,"median":-49.723226,"eighty":-38.189896,"marketCap":2410077328},{"date":"2024-08-30","current":-43.2618,"twenty":-62.33047,"median":-48.934948,"eighty":-38.276606,"marketCap":2460385093},{"date":"2024-09-06","current":-44.299706,"twenty":-62.063778,"median":-48.270052,"eighty":-38.375033,"marketCap":2519412871},{"date":"2024-09-13","current":-41.079839,"twenty":-61.869081,"median":-45.980618,"eighty":-38.588613,"marketCap":2336292606},{"date":"2024-09-20","current":-46.127835,"twenty":-61.368222,"median":-44.806865,"eighty":-38.861791,"marketCap":2623382252},{"date":"2024-09-27","current":-43.379744,"twenty":-60.747027,"median":-44.736098,"eighty":-39.046612,"marketCap":2467092795},{"date":"2024-10-04","current":-42.412604,"twenty":-60.551887,"median":-44.517902,"eighty":-39.324835,"marketCap":2412089639},{"date":"2024-10-11","current":-40.667036,"twenty":-60.382766,"median":-44.458898,"eighty":-39.52313,"marketCap":2312815649},{"date":"2024-10-18","current":-43.356155,"twenty":-60.203473,"median":-44.063818,"eighty":-39.574912,"marketCap":2465751255},{"date":"2024-10-25","current":-42.990529,"twenty":-60.177247,"median":-43.698192,"eighty":-39.657154,"marketCap":2444957379},{"date":"2024-10-31","current":-42.837202,"twenty":-60.01213,"median":-43.662809,"eighty":-39.673778,"marketCap":2436237366},{"date":"2024-11-08","current":-46.068863,"twenty":-59.381569,"median":-43.651015,"eighty":-39.804577,"marketCap":2620028401},{"date":"2024-11-15","current":-32.980568,"twenty":-59.208121,"median":-43.63922,"eighty":-39.654701,"marketCap":2400853462},{"date":"2024-11-22","current":-30.044833,"twenty":-58.542987,"median":-43.538968,"eighty":-38.997903,"marketCap":2187143689},{"date":"2024-11-29","current":-32.283796,"twenty":-58.232975,"median":-43.444613,"eighty":-38.328163,"marketCap":2350131206},{"date":"2024-12-06","current":-31.17825,"twenty":-58.005312,"median":-43.379744,"eighty":-38.000071,"marketCap":2269651893},{"date":"2024-12-13","current":-26.821099,"twenty":-57.745125,"median":-43.279491,"eighty":-37.543086,"marketCap":1952468717},{"date":"2024-12-20","current":-26.031423,"twenty":-56.915781,"median":-43.120267,"eighty":-36.394765,"marketCap":1894983493},{"date":"2024-12-27","current":-27.044066,"twenty":-56.349294,"median":-43.061296,"eighty":-36.125261,"marketCap":1968699839},{"date":"2025-01-03","current":-26.914002,"twenty":-56.207672,"median":-43.037707,"eighty":-35.33784,"marketCap":1959231684},{"date":"2025-01-10","current":-28.298257,"twenty":-56.136384,"median":-42.978735,"eighty":-34.953504,"marketCap":2059999900},{"date":"2025-01-17","current":-27.034776,"twenty":-55.969133,"median":-42.872585,"eighty":-33.374909,"marketCap":1968023542},{"date":"2025-01-24","current":-32.158189,"twenty":-55.840266,"median":-42.689773,"eighty":-32.852839,"marketCap":2340987506},{"date":"2025-01-31","current":-31.530712,"twenty":-55.653821,"median":-42.565931,"eighty":-32.283796,"marketCap":2295309701},{"date":"2025-02-07","current":-31.405216,"twenty":-55.437216,"median":-42.394913,"eighty":-32.036945,"marketCap":2286174140},{"date":"2025-02-14","current":-29.805151,"twenty":-55.004006,"median":-42.206678,"eighty":-31.677123,"marketCap":2169695737},{"date":"2025-02-21","current":-29.512328,"twenty":-54.631116,"median":-41.999801,"eighty":-31.530712,"marketCap":2148379428},{"date":"2025-02-28","current":-25.768383,"twenty":-54.494024,"median":-41.775708,"eighty":-31.373843,"marketCap":1875835192},{"date":"2025-03-07","current":-28.226,"twenty":-54.39406,"median":-41.609082,"eighty":-31.094637,"marketCap":2054739928},{"date":"2025-03-14","current":-27.138374,"twenty":-54.151294,"median":-41.292708,"eighty":-30.560445,"marketCap":1975565066},{"date":"2025-03-21","current":-29.020804,"twenty":-53.671473,"median":-41.068045,"eighty":-30.21301,"marketCap":2112598481},{"date":"2025-03-28","current":-28.173711,"twenty":-53.493253,"median":-40.922206,"eighty":-29.826066,"marketCap":2050933444},{"date":"2025-04-04","current":-16.223536,"twenty":-52.780375,"median":-40.788853,"eighty":-29.478125,"marketCap":1428303862},{"date":"2025-04-11","current":-15.26259,"twenty":-52.725539,"median":-40.592885,"eighty":-29.073094,"marketCap":1343703153},{"date":"2025-04-17","current":-17.504797,"twenty":-52.648767,"median":-40.36956,"eighty":-28.807616,"marketCap":1541104808},{"date":"2025-04-25","current":-18.630229,"twenty":-51.927664,"median":-39.710836,"eighty":-28.715432,"marketCap":1640186719},{"date":"2025-05-02","current":-24.014988,"twenty":-51.631545,"median":-39.587801,"eighty":-28.276198,"marketCap":2114255557},{"date":"2025-05-09","current":-20.891121,"twenty":-50.318205,"median":-39.192738,"eighty":-28.046644,"marketCap":1839233409},{"date":"2025-05-16","current":-18.305859,"twenty":-49.931606,"median":-38.624431,"eighty":-27.822323,"marketCap":1932311557},{"date":"2025-05-23","current":-18.60193,"twenty":-49.805481,"median":-38.19927,"eighty":-27.481395,"marketCap":1963563934},{"date":"2025-05-30","current":-18.941329,"twenty":-49.745161,"median":-38.000071,"eighty":-27.137812,"marketCap":1999389828},{"date":"2025-06-06","current":-19.230179,"twenty":-49.665648,"median":-37.795014,"eighty":-26.986466,"marketCap":2029879952},{"date":"2025-06-13","current":-19.136302,"twenty":-49.503879,"median":-37.543086,"eighty":-26.644583,"marketCap":2019970662},{"date":"2025-06-20","current":-18.977435,"twenty":-49.032283,"median":-37.168124,"eighty":-26.449487,"marketCap":2003201094}],"updateTime":1750600899746}}}